- Home
- DSY vs ACET Comparison
DSY vs ACET Comparison
Compare DSY & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- ACET
- Stock Information
- Founded
- DSY 2020
- ACET 1947
- Country
- DSY China
- ACET United States
- Employees
- DSY N/A
- ACET N/A
- Industry
- DSY
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- ACET Health Care
- Exchange
- DSY Nasdaq
- ACET Nasdaq
- Market Cap
- DSY 77.6M
- ACET 64.9M
- IPO Year
- DSY N/A
- ACET N/A
- Fundamental
- Price
- DSY $1.29
- ACET $0.67
- Analyst Decision
- DSY
- ACET Buy
- Analyst Count
- DSY 0
- ACET 6
- Target Price
- DSY N/A
- ACET $6.00
- AVG Volume (30 Days)
- DSY 11.3K
- ACET 412.2K
- Earning Date
- DSY 02-10-2025
- ACET 08-12-2025
- Dividend Yield
- DSY N/A
- ACET N/A
- EPS Growth
- DSY 120.37
- ACET N/A
- EPS
- DSY 0.01
- ACET N/A
- Revenue
- DSY $7,323,356.00
- ACET N/A
- Revenue This Year
- DSY N/A
- ACET N/A
- Revenue Next Year
- DSY N/A
- ACET N/A
- P/E Ratio
- DSY $102.83
- ACET N/A
- Revenue Growth
- DSY 16.37
- ACET N/A
- 52 Week Low
- DSY $0.75
- ACET $0.45
- 52 Week High
- DSY $6.98
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- DSY 42.27
- ACET 43.24
- Support Level
- DSY $1.27
- ACET $0.72
- Resistance Level
- DSY $1.39
- ACET $0.84
- Average True Range (ATR)
- DSY 0.07
- ACET 0.06
- MACD
- DSY -0.00
- ACET -0.02
- Stochastic Oscillator
- DSY 45.28
- ACET 0.00
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.